D&D Pharmatech Signs Obesity Treatment Research Contract with Pfizer

by Lim Chunhan

Published 16 Apr.2026 13:38(KST)

D&D Pharmatech announced on the 16th that it has signed a research service contract with Pfizer in the United States for the development of an oral peptide dual agonist (obesity treatment) formulation.

The contract amount is equivalent to 42.64% of last year’s sales. The contract period runs until November 30, 2026.